Caladrius Biosciences, Inc. (CLBS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
110 ALLEN ROAD BASKING RIDGE, NJ 07920 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 32,154 | 24,647 | 16,512 | 22,768 | 37,818 | 51,885 | |||
| Cash and cash equivalents | 32,154 | 24,647 | 16,512 | 14,032 | 10,299 | ||||
| Short-term investments | 25,917 | ||||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 8,736 | 27,519 | 25,968 | ||||||
| Receivables | 234 | ||||||||
| Other undisclosed current assets | 39,722 | 71,535 | 18,819 | 3,204 | 6,288 | 8,991 | |||
| Total current assets: | 71,876 | 96,182 | 35,331 | 25,972 | 44,106 | 61,110 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 296 | 62 | 57 | 100 | 165 | 257 | |||
| Other noncurrent assets | 528 | 764 | 614 | 1,081 | 309 | 1,434 | |||
| Other undisclosed noncurrent assets | 334 | 575 | |||||||
| Total noncurrent assets: | 1,158 | 826 | 671 | 1,181 | 474 | 2,266 | |||
| TOTAL ASSETS: | 73,034 | 97,008 | 36,002 | 27,153 | 44,580 | 63,376 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6,383 | 4,523 | 3,506 | 5,976 | 5,619 | 9,154 | |||
| Accounts payable | 2,655 | 1,934 | 1,020 | 1,490 | 762 | 1,343 | |||
| Accrued liabilities | 3,728 | 2,589 | 2,486 | 4,486 | 4,857 | 7,811 | |||
| Debt | 159 | ||||||||
| Total current liabilities: | 6,383 | 4,523 | 3,506 | 5,976 | 5,619 | 9,313 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 327 | 485 | 254 | 624 | 1,507 | 3,873 | |||
| Other liabilities | 327 | 485 | 254 | 624 | 1,507 | 3,873 | |||
| Total noncurrent liabilities: | 327 | 485 | 254 | 624 | 1,507 | 3,873 | |||
| Total liabilities: | 6,710 | 5,008 | 3,760 | 6,600 | 7,126 | 13,186 | |||
| Equity | |||||||||
| Equity, attributable to parent | 66,578 | 92,254 | 32,496 | 20,816 | 37,726 | 50,508 | |||
| Preferred stock | 0 | ||||||||
| Common stock | 8 | 60 | 19 | 11 | 10 | 9 | |||
| Treasury stock, value | (708) | (708) | (708) | (708) | (708) | (708) | |||
| Additional paid in capital | 574,548 | 545,988 | 458,748 | 438,911 | 436,433 | 433,044 | |||
| Accumulated other comprehensive income (loss) | (29) | (70) | (13) | 2 | (32) | (28) | |||
| Accumulated deficit | (507,241) | (453,016) | (425,550) | (417,400) | (397,977) | (381,810) | |||
| Equity, attributable to noncontrolling interest | (254) | (254) | (254) | (263) | (272) | (318) | |||
| Total equity: | 66,324 | 92,000 | 32,242 | 20,553 | 37,454 | 50,190 | |||
| TOTAL LIABILITIES AND EQUITY: | 73,034 | 97,008 | 36,002 | 27,153 | 44,580 | 63,376 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 1,900 | |||||||
| Gross profit: | 1,900 | |||||||
| Operating expenses | (57,601) | (29,050) | (19,145) | (20,092) | (16,987) | (27,593) | ||
| Other undisclosed operating loss | (1,900) | |||||||
| Operating loss: | (57,601) | (29,050) | (19,145) | (20,092) | (16,987) | (27,593) | ||
| Nonoperating income (expense) | 897 | 76 | 132 | 740 | 819 | (105) | ||
| Investment income, nonoperating | 1,052 | 151 | ||||||
| Other nonoperating income (expense) | (155) | (75) | 132 | 740 | 824 | 273 | ||
| Interest and debt expense | (5) | (378) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (56,704) | (28,974) | (19,013) | (19,352) | (16,173) | (28,075) | ||
| Other undisclosed income from continuing operations before income taxes | 5 | 378 | ||||||
| Loss from continuing operations before income taxes: | (56,704) | (28,974) | (19,013) | (19,352) | (16,168) | (27,698) | ||
| Income tax benefit | 2,479 | 1,508 | 10,872 | 11,527 | ||||
| Loss from continuing operations: | (54,225) | (27,466) | (8,141) | (19,352) | (16,168) | (16,171) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | (27,466) | (8,141) | (19,352) | (16,168) | 22,228 | |
| Income from discontinued operations | 38,399 | |||||||
| Net income (loss): | (54,225) | (27,466) | (8,141) | (19,352) | (16,168) | 22,228 | ||
| Other undisclosed net income (loss) attributable to parent | (9) | (9) | 1 | 751 | ||||
| Net income (loss) available to common stockholders, diluted: | (54,225) | (27,466) | (8,150) | (19,361) | (16,167) | 22,979 | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (54,225) | (27,466) | (8,141) | (19,352) | (16,168) | 22,228 | ||
| Other comprehensive income (loss) | 41 | (57) | (15) | 34 | (4) | (28) | ||
| Comprehensive income (loss): | (54,184) | (27,523) | (8,156) | (19,318) | (16,172) | 22,200 | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (9) | (9) | 1 | 751 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (54,184) | (27,523) | (8,165) | (19,327) | (16,171) | 22,951 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.